Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an independent medical education grant from Sandoz Inc., a Novartis Division.
Release Date: March 8, 2018
Expiration Date: March 8, 2019
Media: Internet - based
Many biologic therapies serve as key components of standard-of-care management approaches for patients with hematologic malignancies, including active treatment and supportive care. However, many such biologic options are quite costly, potentially limiting the access of treatments which may improve outcomes for patients. Biosimilars are biologics that are highly similar to the reference biologic products, and they may offer the potential to bridge the treatment gap. Many health care providers lack familiarity with the complex regulatory approval process pathway for biosimilars, as well as safety and efficacy data for biosimilars that are emerging or have already been approved. This activity will provide clinicians with updates on the latest clinical advancements in biosimilar treatments for hematologic malignancies.
This activity features video interviews with leading clinical experts who will review and discuss aspects of biosimilars important to cancer care providers, including basic scientific principles of biosimilars and their production, FDA regulatory pathways and requirements, the intricacies of clinical study design and data interpretation, biosimilar agents in different stages of development for the management of patients with hematologic malignancies, and practical issues related to potential clinical integration.
This activity is supported by an independent medical education grant from Sandoz, Inc., a Novartis Division.
Instructions for This Activity and Receiving Credit
This educational activity is intended for hematologists, medical oncologists, and other health care professionals interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic malignancies are also invited to participate.
At the conclusion of this activity, you should be better prepared to:
Edward Li, PharmD, MPH, BCOP
Professor, Department of Pharmacy Practice
University of New England College of Pharmacy
Disclosure:Pfizer, Eli Lilly, Heron Therapeutics, Mylan; Speakers Bureau: Pfizer
Pamela S. Becker, MD, PhD
Professor of Medicine, Division of Hematology
University of Washington School of Medicine
Disclosure:Grant/Research Support: AbbVie, Amgen, Bristol-Myers Squibb, GlycoMimetics, JW Pharmaceutical; Consultant: Member of a Scientific Steering Committee, Pfizer; Medical Advisor, Caremark/Accordant
Bertrand Coiffier, MD, PhD
Professor of Hematology, Department of Hematology
Hospices Civils de Lyon
Université Claude Bernard
Disclosure: Grant/Research Support: Roche, Celgene; Consultant: Celltrion, Pfizer, Apobiologix, Novartis
Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics
Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: GlaxoSmithKline, Janssen, Roche, Gilead Sciences, Bristol-Myers Squibb; Consultant: Genentech/Roche, GlaxoSmithKline, Gilead Sciences, Celgene, Pharmacyclics/Janssen, Amgen, Takeda, NanoString Technologies, Adaptive Biotechnologies
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
ASCO: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your Patients
June 1, 2018
June 1, 2018
ASCO: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary Cancers
June 1, 2018
ASCO: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of Immunotherapy
June 2, 2018
June 3, 2018
Jun 30, 2018
Jun 30, 2018
Jun 30, 2018